The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Oncol.
Sec. Hematologic Malignancies
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1494384
Real-world Experiences with Brentuximab Vedotion-Based Regimens in Systemic Anaplastic Large Cell Lymphoma: A Multicenter Retrospective Study
Provisionally accepted
Zhiqiang Zhao
1
Qinchuan Yu
1
Jianxia He
2
Jie Tao
3*
Yanfeng Xi
1*
Yujiao Guo
4
Yanhong Luo
4*
Liping Su
1*
Lieyang Wang
1*- 1 Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi Province, China
- 2 Shanxi Provincial People's Hospital, Taiyuan, Shanxi Province, China
- 3 First Hospital of Shanxi Medical University, Taiyuan, Shaanxi, China
- 4 Department of Health Statistics, Shanxi Medical University, Taiyuan, Shanxi Province, China
Background: Brentuximab vedotin (BV) has demonstrated high remission rates in clinical trials for systemic anaplastic large cell lymphoma (sALCL), yet its real-world effectiveness in China remains unconfirmed. This retrospective observational study evaluates BVbased regimens in patients with sALCL, treated from 2020 to 2023.A multi-center observational retrospective study was conducted on patients with sALCL received BV plus cyclophosphamide, doxorubicin, and prednisone (CHP) upfront or BV plus gemcitabine, oxaliplatin (GemOx), gemcitabine, cisplatin , dexamethasone(GDP), or isocyclophosphamide, carboplatin, etoposide (ICE)for later lines.Primary endpoints were complete response rate (CRR) and overall response rate (ORR); secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of response (DOR), and the incidence of adverse events (AEs).Results: Among the 38 patients (28 newly diagnosed and 10 with refractory/relapsed disease), the ORR were 100% (with 89.3% CR) for newly diagnosed patients and 70% (with 50% CR) for refractory/relapsed patients. The median duration of response was 14 months for newly diagnosed patients and 23.8 months for those with refractory/relapsed disease. 2-year Survival rates were 100% for newly diagnosed patients and 80% for refractory/relapsed patients, with 2-year PFS rates of 92.8% and 70%, respectively. Neurological toxicities were commonly observed but resolved following the completion of treatment.BV has proven to be effective and well-tolerated in realworld settings for the treatment of sALCL, reinforcing its potential as a promising option for first-line or subsequent therapy. The sustained efficacy observed post-CR suggests that these patients may have a prolonged disease control.
Keywords: Real world study, Lymphoma, China, brentuximab vedodin, systemic anaplastic large cell lymphoma(sALCL)
Received: 10 Sep 2024; Accepted: 13 Dec 2024.
Copyright: © 2024 Zhao, Yu, He, Tao, Xi, Guo, Luo, Su and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jie Tao, First Hospital of Shanxi Medical University, Taiyuan, 030001, Shaanxi, China
Yanfeng Xi, Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi Province, China
Yanhong Luo, Department of Health Statistics, Shanxi Medical University, Taiyuan, 030001, Shanxi Province, China
Liping Su, Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi Province, China
Lieyang Wang, Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.